Company profile
MUSTANG BIO, INC.
NASDAQ:MBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RELMAPIRAZIN | phase1_2 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05360238 | phase1_2 | terminated | 2022-05-24 | 2024-04-12 | Mustang Bio | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL |
| NCT04109482 | phase1_2 | terminated | 2020-02-17 | 2023-05-17 | Mustang Bio | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. |
FDA applications (0)
No records yet.